Show notes
Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV.
Topics include:
Considerations for CMV management in HCT recipients
New definitions of refractory and resistant CMV
Risk factors for refractory and resistant CMV infections
Identifying drug-resistant CMV
Treatment options for refractory/resistant CMV
To view the full educational program and download the accompanying slides, visit our website:https://bit.ly/4lfrDTT
Presenters:
Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID
Professor and Chair
G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
President, The International Immunocompromised Host Society (ICHS)
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, Texas
Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.